Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the second quarter 2024 by approximately $0.18.
For comments and feedback: editorial@rttnews.com